13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05154734
(ClinicalTrials.gov)
October 30, 20217/12/2021Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum DisordersEfficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders (BEAT NMO)NMO Spectrum DisorderDrug: BelimumabTianjin Medical University General HospitalNULLRecruiting18 YearsN/AAll12Phase 1/Phase 2China
2NCT04767698
(ClinicalTrials.gov)
October 1, 202118/2/2021Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple SclerosisAddition of Belimumab to B-cell Depletion to Produce Prolonged Remission of Relapsing-remitting Multiple Sclerosis Disease ActivityMultiple SclerosisDrug: Belimumab;Drug: Short-course Ocrelizumab;Drug: Continued OcrelizumabJohns Hopkins UniversityGlaxoSmithKlineTerminated18 YearsN/AAll3Phase 2United States